Dupilumab provides favourable long-term safety and efficacy in children aged ≥ 6 to < 12 years with uncontrolled severe atopic dermatitis: results from an open-label phase IIa study and subsequent phase III open-label extension study

M. J. Cork, D. Thaçi, L. F. Eichenfield, P. D. Arkwright, X. Sun, Z. Chen, B. Akinlade, S. Boklage, I. Guillemin, M. P. Kosloski, M. A. Kamal, J. T. O’Malley, N. Patel, N. M.H. Graham, A. Bansal*

*Corresponding author for this work

Fingerprint

Dive into the research topics of 'Dupilumab provides favourable long-term safety and efficacy in children aged ≥ 6 to < 12 years with uncontrolled severe atopic dermatitis: results from an open-label phase IIa study and subsequent phase III open-label extension study'. Together they form a unique fingerprint.

Medicine & Life Sciences